Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NMS-03305293 |
| Trade Name | |
| Synonyms | NMS03305293|NMS 03305293|NMS-293|NMS293|NMS 293 |
| Drug Descriptions |
NMS-03305293 inhibits PARP1, potentially leading to decreased DNA damage repair, increased tumor cell apoptosis, and inhibition of tumor growth (Mol Cancer Ther (2023) 22 (12_Supplement): LB_A12, NCI Thesaurus). |
| DrugClasses | PARP-1 Inhibitor 13 |
| CAS Registry Number | NA |
| NCIT ID | C167278 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| NMS-03305293 | NMS-03305293 | 0 | 1 |
| NMS-03305293 + Temozolomide | NMS-03305293 Temozolomide | 0 | 2 |
| NMS-03305293 + Topotecan | NMS-03305293 Topotecan | 0 | 1 |